Market expansion ImpriMed has demonstrated rapid geographic reach with deployment across more than 40 U.S. states and growing clinical capabilities in both veterinary and human healthcare. This presents an opportunity to upsell expanded testing services in existing states and to pursue partnerships with hospitals and specialty clinics expanding precision oncology offerings.

Clinical capability Recent launches in advanced PARR and flow cytometry for feline lymphoma and ex vivo drug sensitivity data at major conferences highlight expanded test menus and data-driven insights. Target oncology practices and veterinary centers seeking comprehensive diagnostic and predictive capabilities to differentiate their cancer care.

Strategic partnerships Participation in Mayo Clinic Platform Accelerate and investor-backed Series A fundraising signals strong validation and potential collaboration opportunities with large health systems and research partner networks to co-develop AI-driven precision oncology solutions.

Human and animal health convergence With current veterinary traction and plans to extend AI-driven approaches to human healthcare, there is a cross-market opportunity to package integrated AI-based prediction platforms or modular DRP services for multi-species oncology programs, appealing to academic centers and multisite clinics pursuing personalized medicine.

Financial and growth momentum Revenue scale up and a solid funding backbone (multi-million revenue range and $35M raised) provide budgetary room for enterprise sales, pilot programs, and long-term contracts with tiered service levels, enabling tailored pricing strategies for clinics, hospitals, and veterinary networks.